Intervention

Recombinant EphB4-HSA Fusion Protein

ClinicalTrials.gov intervention label

Clinical trials5
Recruiting0
Common conditions25
Lead sponsors shown2

Clinical trials

5 shown
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT04033432 · 2019-09-20
UNKNOWN
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475NCT03049618 · 2017-03-10
COMPLETED
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsNCT02717156 · 2016-11-21
ACTIVE_NOT_RECRUITING
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerNCT02767921 · 2016-08-02
TERMINATED
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsNCT02495896 · 2015-09-03
ACTIVE_NOT_RECRUITING

Common conditions

Head and Neck Squamous Cell Carcinoma2Recurrent Non-Small Cell Lung Carcinoma2Stage IIIA Non-Small Cell Lung Cancer2Stage IIIB Non-Small Cell Lung Cancer2Stage IV Non-Small Cell Lung Cancer2ALK Gene Mutation1BRAF Gene Mutation1Castration Levels of Testosterone1Castration-Resistant Prostate Carcinoma1Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents1EGFR Gene Mutation1Infiltrating Bladder Urothelial Carcinoma1Metastatic Head and Neck Carcinoma1Metastatic Pancreatic Adenocarcinoma1Metastatic Prostate Adenocarcinoma1Non-Resectable Cholangiocarcinoma1Pancreatic Adenocarcinoma1Progressive Disease1Prostate Cancer1Prostate Carcinoma Metastatic in the Bone1Prostate Carcinoma Metastatic in the Soft Tissue1PSA Progression1Recurrent Bladder Carcinoma1Recurrent Gallbladder Carcinoma1Recurrent Head and Neck Carcinoma1

Trial status mix

ACTIVE_NOT_RECRUITING2
COMPLETED1
TERMINATED1
UNKNOWN1

Phase mix

PHASE23
PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.